EMA Advances New Pharmaceutical Legislation Implementation, Prioritising Antibiotic Vouchers and Regulatory Sandbox

EMA's September 2026 Management Board meeting signals a tightening implementation timeline for the new EU pharmaceutical legislation (NPL), with direct consequences for manufacturers operating under or exporting into the EU regulatory framework. Initiatives flagged for early entry into force, transferable exclusivity vouchers for priority antibiotics, the regulatory sandbox, and shortage management mechanisms, are now active workstreams, not future-state planning.

For plant heads and QA directors, the shortage management provisions carry the most immediate operational weight. The Critical Medicines Act sits alongside the NPL as a parallel track, and EMA confirmed the Board welcomed progress on measures to strengthen availability and supply of critical medicines across the EU. Manufacturers of critical or shortage-prone products should expect evolving reporting obligations and supply continuity requirements as implementation details emerge through the NPL hub on the EMA website.

The regulatory sandbox provision is worth monitoring closely. Designed to allow controlled testing of innovative regulatory approaches, it could affect how novel manufacturing technologies, including continuous manufacturing or advanced therapy medicinal product (ATMP) processes, are assessed prior to formal submission. Regulatory affairs leads evaluating EU market entry strategies for novel modalities should track sandbox eligibility criteria as EMA publishes further guidance.

On the clinical trials side, the Clinical Trials Information System (CTIS) has processed authorisation and management of more than 14,000 trials since its 2022 launch, with over 200 new applications received monthly. A modernisation initiative begun in 2025 is now being scoped to accommodate Biotech Act functionalities following the European Commission's December 2025 proposal adoption. Sponsors running multi-country EU trials should factor CTIS system development cycles into their submission planning, particularly for trials that may fall under Biotech Act scope.

EMA's mid-year operational data showed 29 human medicine applications received in the first half of 2026, consistent with 2025 levels, while veterinary medicine initial marketing authorisation applications dropped to seven from twelve in the same period last year. Scientific advice requests increased for both human and veterinary medicines, reflecting continued developer engagement ahead of the legislative transition.

The nomination process for the next EMA Executive Director is also underway, with an extraordinary Board meeting to be convened once the European Commission submits a shortlist, a leadership transition that coincides with one of the most substantive regulatory reform cycles the Agency has managed in over a decade.

The publication of EMA's full 2026 mid-year report, expected shortly, will provide the next measurable checkpoint on NPL implementation progress across the European Medicines Regulatory Network.

Source: European Medicines Agency (EMA) via ema.europa.eu, 1 October 2026.